Literature DB >> 16224788

Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450.

Christopher R Otey1, Geethani Bandara, James Lalonde, Katsuyuki Takahashi, Frances H Arnold.   

Abstract

Testing the toxicities and biological activities of the human metabolites of drugs is important for development of safe and effective pharmaceuticals. Producing these metabolites using human cytochrome P450s is difficult, however, because the human enzymes are costly, poorly stable, and slow. We have used directed evolution to generate variants of P450 BM3 from Bacillus megaterium that function via the "peroxide shunt" pathway, using hydrogen peroxide in place of the reductase domain, oxygen and NADPH. Here, we report further evolution of the P450 BM3 heme domain peroxygenase to enhance production of the authentic human metabolites of propranolol by this biocatalytic route. This system offers a versatile, cost-effective, and scaleable route to the synthesis of drug metabolites. Copyright 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16224788     DOI: 10.1002/bit.20744

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  25 in total

Review 1.  Engineered proteins: redox properties and their applications.

Authors:  Shradha Prabhulkar; Hui Tian; Xiaotang Wang; Jun-Jie Zhu; Chen-Zhong Li
Journal:  Antioxid Redox Signal       Date:  2012-06-11       Impact factor: 8.401

2.  Directed evolution methods for overcoming trade-offs between protein activity and stability.

Authors:  Samuel D Stimple; Matthew D Smith; Peter M Tessier
Journal:  AIChE J       Date:  2019-10-09       Impact factor: 3.993

3.  Diversification of catalytic function in a synthetic family of chimeric cytochrome p450s.

Authors:  Marco Landwehr; Martina Carbone; Christopher R Otey; Yougen Li; Frances H Arnold
Journal:  Chem Biol       Date:  2007-03

4.  Engineering and analysis of a self-sufficient biosynthetic cytochrome P450 PikC fused to the RhFRED reductase domain.

Authors:  Shengying Li; Larissa M Podust; David H Sherman
Journal:  J Am Chem Soc       Date:  2007-10-04       Impact factor: 15.419

5.  Multistage Reactive Transmission-Mode Desorption Electrospray Ionization Mass Spectrometry.

Authors:  Kevin C Peters; Troy J Comi; Richard H Perry
Journal:  J Am Soc Mass Spectrom       Date:  2015-06-20       Impact factor: 3.109

Review 6.  Peroxygenase reactions catalyzed by cytochromes P450.

Authors:  Osami Shoji; Yoshihito Watanabe
Journal:  J Biol Inorg Chem       Date:  2014-02-06       Impact factor: 3.358

7.  Enantioselective alpha-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3.

Authors:  Marco Landwehr; Lisa Hochrein; Christopher R Otey; Alex Kasrayan; Jan-E Bäckvall; Frances H Arnold
Journal:  J Am Chem Soc       Date:  2006-05-10       Impact factor: 15.419

Review 8.  Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications.

Authors:  Zhong Li; Yuanyuan Jiang; F Peter Guengerich; Li Ma; Shengying Li; Wei Zhang
Journal:  J Biol Chem       Date:  2019-12-06       Impact factor: 5.157

9.  A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds.

Authors:  Andrew M Sawayama; Michael M Y Chen; Palaniappan Kulanthaivel; Ming-Shang Kuo; Horst Hemmerle; Frances H Arnold
Journal:  Chemistry       Date:  2009-11-02       Impact factor: 5.236

10.  Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli.

Authors:  Peter H Bui; Oliver Hankinson
Journal:  Mol Pharmacol       Date:  2009-08-27       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.